Platform-focused PipelineA platform-centered approach (DPEP-1 / LSALT Peptide) provides durable R&D leverage: multiple indications can be pursued from shared science, lowering marginal development cost per program and improving partner appeal. This structural focus supports long-term licensing or co-development opportunities.

Differentiated Antibody ProgramA monoclonal antibody targeting extracellular histones addresses a distinct biological mechanism in acute organ injury, offering potential first-in-class or differentiated positioning. Such a specialized asset can attract strategic partners and grant priority development pathways in high-unmet-need acute indications.

Partnerable Non-commercial Business ModelAs a clinical-stage biotech, Arch’s structural business model relies on licensing/partnerships and financings rather than product sales. That model is durable for early-stage developers: it enables value realization via milestone/royalty streams and lets the company de-risk development by transferring commercialization burden to partners.

Bears Say

Negative Shareholders' EquityNegative shareholders’ equity is a fundamental solvency concern that limits financial flexibility and increases refinancing and dilution risk. Structurally impaired capital reduces bargaining power with partners and lenders and can constrain long-term strategic options unless equity or asset injections restore solvency.

Zero And Volatile RevenueThe absence of recurring revenues and volatile historical income means the company lacks internal funding from operations. This structural revenue instability forces dependence on external financing or milestone deals, reducing runway visibility and raising execution risk for ongoing clinical programs.

Persistent Negative Cash FlowSustained negative operating and free cash flow implies ongoing cash burn and recurring funding needs. Even with modest improvement, the company remains reliant on equity or partner funding, creating persistent refinancing risk and potential program delays if capital access tightens over the next several months.

Arch Biopartners News

Arch Biopartners publishes data linking cytokine IL-32 to inflammation, DKD

Arch Biopartners (ACHFF) announced that a scientific team led by Dr. Justin Chun at the University of Calgary...

7d ago

Arch Biopartners appoints Patrick Vink as chairman of the board

Arch Biopartners (ACHFF) announced the appointment of Dr. Patrick Vink as Chairman of the Company’s Board of Directors,...

1M ago

Arch granted ethics approval for St. Michaels participation in Phase II trial

Arch Biopartners (ACHFF) announced that the University Health Network Research Ethics Board has granted ethics approval for St....

2M ago

Arch Biopartners’ LSALT Peptide Study: A Promising Step in AKI Prevention

Arch Biopartners (($TSE:ARCH)) announced an update on their ongoing clinical study. Arch Biopartners is conducting a Phase 2...

4M ago

ARCH

ARCH FAQ

What was Arch Biopartners’s price range in the past 12 months?

Arch Biopartners lowest stock price was C$0.67 and its highest was C$1.95 in the past 12 months.

What is Arch Biopartners’s market cap?

Arch Biopartners’s market cap is C$63.59M.

When is Arch Biopartners’s upcoming earnings report date?

Arch Biopartners’s upcoming earnings report date is Mar 04, 2026 which is in 16 days.

How were Arch Biopartners’s earnings last quarter?

Currently, no data Available

Is Arch Biopartners overvalued?

According to Wall Street analysts Arch Biopartners’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Arch Biopartners pay dividends?

Arch Biopartners does not currently pay dividends.

What is Arch Biopartners’s EPS estimate?

Arch Biopartners’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Arch Biopartners have?

Arch Biopartners has 66,933,290 shares outstanding.

What happened to Arch Biopartners’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of Arch Biopartners?

Currently, no hedge funds are holding shares in TSE:ARCH

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Arch Biopartners Stock Smart Score

Underperform

Insider Transactions

Bought Shares

Worth C$414.5K over
the Last 3 Months

Technicals

Fundamentals

Return on Equity

―

Trailing 12-Months

Asset Growth

-82.69%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Arch Biopartners

Arch Biopartners Inc., a biotechnology company, develops technologies for medical or commercial impact. It focuses on developing its lead drug candidate Metablok to treat or prevent dipeptidase-1 mediated organ inflammation in the lungs, liver, or kidneys, which results in organ damage or failure, including in the case of sepsis and COVID-19. The company also develops AB569, a drug candidate for treating or preventing antibiotic resistant bacterial infections, primarily as a topical treatment for wounds. In addition, it develops Borg, a peptide-solid surface interface to inhibit biofilm formation and reduce corrosion; and MetaMx, which are synthetic molecules that target brain tumor initiating cells and invasive glioma cells. The company is based in Toronto, Canada.